|
|
||||||||
The Journal of Immunology, Vol 154, Issue 8 3975-3984, Copyright © 1995 by American Association of Immunologists
ARTICLES |
A Lamarre and PJ Talbot
Virology Research Center, Armand-Frappier Institute, University of Quebec, Laval, Canada.
Molecular mechanisms of in vitro and in vivo virus neutralization by specific Ab remain largely undefined. Murine coronaviruses provide an excellent animal model for such studies. To determine the role of Ab bivalency and the contribution of its Fc portion in the neutralization of viral infectivity and passive protection of mice by an in vitro neutralizing and in vivo protective mAb (7-10A), F(ab')2 and Fab fragments were generated and their biologic properties were examined. The two fragments reacted in ELISA like the whole Ab against viral Ag or specific anti-idiotypic Abs. The affinity constants of the different Ab preparations were determined by surface plasmon resonance using immobilized anti-idiotypic Abs. The apparent affinity constant of the whole Ab molecule was 7.0 x 10(9) M-1 and was reduced 2-fold for F(ab')2 fragments and 14-fold for Fab molecules. Like whole Ab, both F(ab')2 and Fab fragments could neutralize virus in vitro and passively protect mice in vivo. However, the efficiency of in vivo neutralization by Fab fragments was reduced compared with the bivalent molecules, despite almost identical half-lives of both types of Ab fragments. These results demonstrate that in vitro and in vivo virus neutralization mechanisms by this Ab are independent of Fc-mediated functions and bivalency, but are probably influenced by Ab avidity. Also, this is the first report of in vivo protection against a viral infection by Fab fragments of antiviral Ab.
This article has been cited by other articles:
![]() |
M. Perotti, N. Mancini, R. A. Diotti, A. W. Tarr, J. K. Ball, A. Owsianka, R. Adair, A. H. Patel, M. Clementi, and R. Burioni Identification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 Protein J. Virol., January 15, 2008; 82(2): 1047 - 1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. W. Neuman, D. A. Stein, A. D. Kroeker, A. D. Paulino, H. M. Moulton, P. L. Iversen, and M. J. Buchmeier Antisense Morpholino-Oligomers Directed against the 5' End of the Genome Inhibit Coronavirus Proliferation and Growth{dagger} J. Virol., June 1, 2004; 78(11): 5891 - 5899. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mozdzanowska, J. Feng, and W. Gerhard Virus-Neutralizing Activity Mediated by the Fab Fragment of a Hemagglutinin-Specific Antibody Is Sufficient for the Resolution of Influenza Virus Infection in SCID Mice J. Virol., August 1, 2003; 77(15): 8322 - 8328. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ramakrishna, C. C. Bergmann, R. Atkinson, and S. A. Stohlman Control of Central Nervous System Viral Persistence by Neutralizing Antibody J. Virol., April 15, 2003; 77(8): 4670 - 4678. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Drew, M. T. Moss, T. J. Pasieka, C. Grose, W. J. Harris, and A. J. R. Porter Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not J. Gen. Virol., August 1, 2001; 82(8): 1959 - 1963. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Kolb, L. Pewe, J. Webster, S. Perlman, C. B. A. Whitelaw, and S. G. Siddell Virus-Neutralizing Monoclonal Antibody Expressed in Milk of Transgenic Mice Provides Full Protection against Virus-Induced Encephalitis J. Virol., March 15, 2001; 75(6): 2803 - 2809. [Abstract] [Full Text] |
||||
![]() |
D. J. Schofield, J. Glamann, S. U. Emerson, and R. H. Purcell Identification by Phage Display and Characterization of Two Neutralizing Chimpanzee Monoclonal Antibodies to the Hepatitis E Virus Capsid Protein J. Virol., June 15, 2000; 74(12): 5548 - 5555. [Abstract] [Full Text] |
||||
![]() |
E. T. Boder, K. S. Midelfort, and K. D. Wittrup Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity PNAS, September 26, 2000; 97(20): 10701 - 10705. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |